FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS


Date/App# patent app List of recent Antibodies-related patents
03/26/15
20150089680
 Human lambda light chain mice patent thumbnailnew patent Human lambda light chain mice
Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
03/26/15
20150087814
 Chemoenzymatic glycoengineering of antibodies and fc fragments thereof patent thumbnailnew patent Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
The present invention provides for recombinant endo-s mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated glcnac-protein acceptor. Such recombinant endo-s mutants are useful for efficient glycosylation remodeling of iggl-fc domain to provide different antibody glycoforms carrying structurally well-defined fc n-glycans..
University Of Maryland, Baltimore
03/26/15
20150087812
 Human autotaxin antibodies and methods of use patent thumbnailnew patent Human autotaxin antibodies and methods of use
antibodies and compositions capable of binding and, in a particular aspect, inhibiting the lysophosphatidylipase d activity of human autotaxin protein. The antibodies or are useful in detecting human autotaxin protein and treating diseases and disorders associated with unwanted lysophosphatidylipase d and the presence of lysophosphatidic acid, such as cancer and pulmonary diseases..
Janssen Biotech, Inc.
03/26/15
20150087810
 Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof patent thumbnailnew patent Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (mmp), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one mmp protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one mmp protease in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.
03/26/15
20150087806
 Glycopeptide and uses thereof patent thumbnailnew patent Glycopeptide and uses thereof
A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof..
University Of Georgia Research Foundation, Inc.
03/26/15
20150087000
 Diagnostic kits to detect sp22 and sp22 antibodies patent thumbnailnew patent Diagnostic kits to detect sp22 and sp22 antibodies
Oral, topical and injectable contraceptives, which are based on sperm protein 22 kda (sp22) polypeptides and antibodies and infertility diagnostics and kits are provided.. .
U.s. Environmental Protection Agency
03/26/15
20150086991
 Uses of anti-cd40 antibodies patent thumbnailnew patent Uses of anti-cd40 antibodies
The methods of the present invention find use in treatment of cancers and pre-malignant conditions that are associated with cd40-expressing cells. These methods are particularly advantageous with respect to cancers and pre-malignant conditions that are associated with cells expressing both cd40 and cd20, as the methods enable the treatment of patients having a cancer or pre-malignant condition that is refractory to therapy with other oncotherapeutic agents such as anti-cd20 antibodies..
03/26/15
20150086978
 Methods and materials for the detection of dengue virus infection patent thumbnailnew patent Methods and materials for the detection of dengue virus infection
The present invention provides monoclonal antibodies that are specific for the dengue non-structural glycoprotein ns1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including elisa and lateral flow assays, that employ the disclosed antibodies for the early detection of dengue virus infection. Diagnostic kits for the detection of dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies..
Inbios International, Inc.
03/26/15
20150086581
 Fast diagnosis and personalized treatment for acne patent thumbnailnew patent Fast diagnosis and personalized treatment for acne
Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses rt4, rt5, rt7, rt8, rt9, or rt10. Methods for treating acne include administering an effective amount of a drug specifically targeting rt4, rt5, rt7, rt8, rt9, or rt10, such as small molecules, antisense molecules, sirnas, biologics, antibodies, phages, vaccines, or combination thereof..
The Regents Of The University Of California
03/26/15
20150086578
 Human cytomegalovirus vaccine patent thumbnailnew patent Human cytomegalovirus vaccine
Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (cmv) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the ul130 and ul131 components of the gh/gl/ul128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of ul130 and amino acid residues 90-106 of ul131.
Virginia Commonwealth University
03/26/15
20150086577
new patent

Pathogenic phlebovirus isolates and compositions and methods of use


Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus phlebovirus (family bunyaviridae) with a proposed name of heartland virus (hrtlv). Provided herein are nucleotide and amino acid sequences of the phlebovirus isolates, primers and probes that specifically hybridize with the phlebovirus isolates, and antibodies specific for the phlebovirus proteins.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of
03/26/15
20150086576
new patent

Sortase-modified vhh domains and uses thereof


In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided.
Whitehead Institute For Biomedical Research
03/26/15
20150086575
new patent

B cell surface reactive antibodies


The invention relates to antibodies that are reactive to the cell surface of cd19+ b cells, including b-cell chronic lymphocytic leukemia (b-cll) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with cd19+ b cells, such as b-cll.. .
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
03/26/15
20150086574
new patent

Antibodies that specifically bind to tim3


Provided herein are antibodies specific for tim3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation..
Cellerant Therapeutics, Inc.
03/26/15
20150086568
new patent

Anti-vegf antibodies


The invention herein provides isolated antibodies that bind to vegf. The invention further provides methods of making anti-vegf antibodies, and polynucleotides encoding anti-vegf antibodies..
Genentech, Inc.
03/26/15
20150086564
new patent

Novel antibodies anti-spla2-iia and uses thereof


The present invention relates to antibodies anti-spla2-iia and uses thereof.. .
Universite Nice Sophia Antipolis
03/26/15
20150086562
new patent

Anti-cd22 antibodies


Anti-cd22 antibodies, including isolated nucleic acids that encode at least one such anti-cd22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof including therapeutic compositions, methods and devices.. .
Bioatla, Llc
03/26/15
20150086561
new patent

Binding moieties for biofilm remediation


Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human b lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described.
Trellis Bioscience, Llc
03/26/15
20150086560
new patent

Influenza vaccine and therapy


The present invention is directed generally to m1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-m1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-m1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response..
Engen Bio Inc.
03/26/15
20150086559
new patent

Antibody formulation


Anti-cd40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation.
Novartis Ag
03/26/15
20150086558
new patent

Anti-mige antibodies that bind to the junction between ch4 and cemx domains


antibodies binding to junction regions between the ch4 and cεmx domains of membrane-bound ige and uses thereof in treating ige-mediated diseases such as allergic diseases.. .
Academia Sinica
03/26/15
20150086556
new patent

Anti-activin a antibodies and uses thereof


The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.
03/26/15
20150086555
new patent

Anti-hemagglutinin antibody compositions and methods of use thereof


The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection..
Theraclone Sciences, Inc.
03/26/15
20150086552
new patent

Bispecific antibodies and methods of using the same


The present invention relates to antagonizing the activity of il-17a, il-17f and il-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for il-17a and il-17f and a binding entity that binds il-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same..
Bristol-myers Squibb Company
03/26/15
20150086550
new patent

Combination of the application of antibodies for immunostimulation together with glucocorticoids


The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid..
03/26/15
20150086546
new patent

Humanized anti-ccr2 antibodies and methods of use therefor


The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) cc-chemokine receptor 2 (ccr2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian ccr2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods..
Millennium Pharmaceuticals, Inc.
03/26/15
20150086540
new patent

Methods of using an antibody to inhibit wnt-mediated cardiac remodeling


The present invention is directed to monoclonal antibodies and fragments thereof directed to lrp5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases..
Vanderbilt University
03/26/15
20150086483
new patent

Methods for treating idiopathic pulmonary fibrosis


The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (iff) by administering anti-ctgf antibodies. Methods for prognosing individuals with ipf are also provided..
Fibrogen, Inc.
03/26/15
20150086478
new patent

Humanized pan-her antibody compositions


The invention relates to humanized recombinant antibodies targeting the egfr family receptors egfr, her2 and her3, compositions comprising at least one humanized anti-egfr antibody, at least one humanized anti-her2 antibody and at least one humanized anti-her3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple egfr-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies..
Symphogen A/s
03/19/15
20150082466

Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies


The present invention relates to humanisation of antibodies in vivo. The invention provides non-human vertebrates, cells, populations and methods useful for humanising chimaeric antibodies in vivo.
Kymab Limited
03/19/15
20150080785

Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis


This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies etanercept, igf-1, and acetylcholine esterase inhibitors physostigmine, for treatment of alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, etanercept, igf-1, and physostigmine therapeutic agents.
Wedge Therapeutics, Llc
03/19/15
20150080557

Human antibodies that bind human tnf-alpha and methods of preparing the same


Methylglyoxal (mgo)-modified recombinant tnf-alpha antibodies (e.g., adalimumab) are identified. Mgo modification decreases binding between adalimumab and tnf-alpha.
Abbvie Inc.
03/19/15
20150080556

Antibodies against human csf-1r and uses thereof


The present invention relates to antibodies against human csf-1r (csf-1r antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
Hoffmann-la Roche Inc.
03/19/15
20150080267

Method for immunizing an avian species


The present invention relates to a method for generating a plurality of different igy antibodies, by immunizing each of a plurality of avian organisms of the same or different species with a composition comprising a plurality of different antigens, thereby generating a plurality of different igy antibodies.. .
Carviar Aps
03/19/15
20150079612

Assays, antibodies, immunogens and compositions related to 5-fu


The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-fu and/or 5-fu conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma.. .
Wellstat Diagnostics, Llc
03/19/15
20150079610

Chimeric fc-gamma receptor and determination of adcc activity by using the receptor


To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse fcγr3 or mouse fcγr4 with the transmembrane domain/intracellular domain of human γ chain or human fcγr3, and expressed the chimeric molecules in human nk92 cells. It was revealed that the adcc activity can be induced by the chimeric receptors produced by any combination of the domains, and that the adcc activity of mouse antibodies can be measured using the chimeric receptors of the present invention..
03/19/15
20150079604

Soluble immunoreactive treponema pallidum tpn47 antigens


The invention concerns soluble variants of treponema pallidum antigen 47 (tpn47 antigen) comprising at least domain b, or at least domains a and b, optionally domain d of the complete tpn47 protein molecule with the proviso that all antigens lack domain c (amino acid residues 224 to 351) of tpn47. The tpn47 antigens can be fused to a chaperone.
Roche Diagnostics Operations, Inc.
03/19/15
20150079127

Canine babesiosis vaccine antigen


The present invention relates to the field of veterinary parasitology, especially of canine babesiosis. In particular the invention relates to a polypeptide being a novel canine babesia antigen (cba), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids.
Intervet Inc.
03/19/15
20150079123

Live, attenuated rubella vector to express vaccine antigens


Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (orf) without an in-frame deletion, a rubella structural protein orf, and a heterologous antigenic insert. In one example, the heterologous antigenic insert is positioned within the rubella structural protein orf.
The United States Of America, As Represented By The Secretary, Dep. Of Health And Human Services
03/19/15
20150079115

Compositions and methods for preventing or relieving symptoms of infections


Food products and/or pharmaceutical preparations including (i) viral neutralizing antibodies or antibody fragments anchored to a probiotic microorganism and (ii) a carrier medium for delivering the viral neutralizing antibodies or antibody fragments anchored to probiotic microorganisms to the gut of a mammal. Also provided are methods of making food products and/or pharmaceutical preparations, which can be used to treat existing viral infections or prevent the spread or transmission of viral infection..
The Johns Hopkins University
03/19/15
20150079109

Anti-pd1 antibodies and their use as therapeutics and diagnostics


Provided are antibodies that specifically bind to programmed death-1 (pd1, pdcd-1, or cd279) and inhibit pd1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by pd1-mediated functions.. .
Beigene, Ltd.
03/19/15
20150079106

Anti-neoplastic uses of artemin antagonists


The invention relates to methods for the prophylaxis and treatment of breast cancer using one or more antagonists of artemin function, such as anti-artemin polynucleotides or anti-artemin antibodies and antibody fragments, and uses of these antagonists. In particular, the invention relates to the resensitisation of therapy-resistance breast cancer cells to anti-cancer therapies by antagonism of artemin functionality..
Auckland Uniservices Limited
03/19/15
20150079101

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
03/19/15
20150079100

Methods of treatments using ctla-4 antibodies


In certain embodiments, the present invention, the present invention provides a method of treating a cancer in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-ctla4 antibody; (b) detecting the level of the anti-ctla4 antibody in a sample of the subject; and (c) increasing the dosage of the anti-ctla4 antibody in the subject if the level of the anti-ctla4 antibody from step (b) is below a threshold exposure level, such that the cancer is treated.. .
Bristol-myers Squibb Company
03/19/15
20150079099

Anti-rantes antibodies


The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine regulated upon activation, normal t-cell expressed, and secreted (rantes, ccl5), thereby modulating the interaction between rantes and one of more of its receptors, such as, e.g., ccr1, ccr3, ccr4 and ccr5, and/or modulating the biological activities of rantes. The invention also relates to the use of these or any anti-rantes antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder..
Novlmmune S.a.
03/19/15
20150079097

S100a4 antibodies and therapeutic uses thereof


The invention relates to antibodies against s100a4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.. .
Lykera Biomed Sa
03/19/15
20150079088

Multispecific antibodies, multispecific activatable antibodies and methods of using the same


The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.
03/19/15
20150079086

Methods for treatment of brain injury utilizing biologics


A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of tnf antagonists.
Tact Ip Llc
03/19/15
20150079082

Optimized fc variants and methods for their generation


The present invention relates to optimized fc variants, methods for their generation, and antibodies and fc fusions comprising optimized fc variants.. .
Xencor, Inc.
03/19/15
20150079080

Novel anti-igf-ir antibodies and uses thereof


The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor i receptor igf-ir and/or capable of specifically inhibiting the tyrosine kinase activity of said igf-ir receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing igf-ir or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the igf-ir receptor.
Merck Sharp & Dohme Corp.; Institute De Recherche Pierre Fabre
03/19/15
20150079075

Anti-cd11a antibodies and uses thereof


Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to cd11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of hiv infection or aids) in a subject that has an hiv infection or aids that include administering at least one of the antibodies or antigen-binding fragments to the subject.
Cytodyn Inc.
03/19/15
20150079070

Hyperglycosylated binding polypeptides


Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a ch1 domain (e.g., a human igg1 ch1 domain), wherein the ch1 domain has an engineered n-linked glycosylation site at amino acid position 114, according to kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation
03/19/15
20150078996

Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders


The present invention relates to mammalian antibodies, designated 12b1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor i receptor (igf-ir), preferably human igf-ir. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein.
Pierre Fabre Medicament
03/12/15
20150074836

Mutations of the parkin gene, compositions, methods and uses


The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes..
Institut National De La Santé Et De La Recherche Médicale
03/12/15
20150073330

Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis


This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies etanercept, igf-1, and acetylcholine esterase inhibitors physostigmine, for treatment of alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, etanercept, igf-1, and physostigmine therapeutic agents.
Wedge Therapeutics, Llc
03/12/15
20150073130

Hybrid constant regions


The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least ch2 and ch3 regions of an igg or iga constant region and cμ3 and cμ4 regions of a cμ constant region.
Jn Bioscience Llc
03/12/15
20150073129

Combination therapy of antibodies against human csf-1r and antibodies agains human pd-l1


The present invention relates to the combination therapy of specific antibodies which bind human csf-1r with specific antibodies which bind human pd-l1.. .
Hoffmann-la Roche Inc.
03/12/15
20150073128

Chromatography ligand


The present invention relates to a chromatography ligand defined by the following formula r1—r2—n(r3)—r4—r5 wherein r1 is a substituted or non-substituted phenyl group; r2 is a hydrocarbon chain comprising 0-4 carbon atoms; r3 is a hydrocarbon chain comprising 1-3 carbon atoms; r4 is a hydrocarbon chain comprising 1-5 carbon atoms; and r5 is oh or h. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane.
Ge Healthcare Bio-sciences Ab
03/12/15
20150073033

Biomarkers for cancer characterization and treatment


Composition and methods for characterizing cancer cells by determining a marker of pkm2 activity. For example, methods are provided for predicting a patient response to a nf-κb, pkcε, pkm2, mek/erk, pin1 or src inhibitor therapy.
Board Of Regents, The University Of Texas System
03/12/15
20150072886

Methods and systems for detecting mhc class i binding peptides


The present invention is based on the discovery that mhc heavy chain monomers immobilized to a solid surface are still capable of forming detectable conformational epitopes and being detected by conformation-dependent antibodies. Methods for detecting peptide binding to hla monomers, and methods for measuring the relative degree of binding between two mhc-binding peptides as well as a method of measurement for the rate of dissociation of peptides from mhc complexes are provided.
Beckman Coulter, Inc.
03/12/15
20150072885

Antibodies and determining deletions in hbv pre-s2 region


A hbs-specific antibody, a lhbs-specific antibody, a wt lhbs-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-s2 deletion mutant lhbs using the immunoassay kit are disclosed herein. The method comprises incubating a biological sample with a first antibody to captured hbs proteins; detecting the lhbs and wt lhbs bound to the immobilized first antibody, respectively; and calculating the amount of the pre-s2 deletion mutant lhbs protein by subtracting the amount of the wt lhbs protein from that of the lhbs protein.
National Health Research Institutes
03/12/15
20150072412

Identification of antigen or ligand-specific binding proteins


The present invention discloses novel methods for the generation, expression and screening of diverse collections of binding proteins such as antibodies or fragments thereof in vertebrate host cells in vitro, for the identification and isolation of ligand- or antigen-specific binding proteins. The methods disclosed herein allow the expression of diverse collections of binding proteins from at least one vector construct, which optionally can give rise to collections of diverse binding proteins upon transfer and expression into vertebrate host cells in situ..
4-antibody Ag
03/12/15
20150072368

Transcription units and the use thereof in expression vectors


Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium..
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
03/12/15
20150072022

Fractional c-reactive protein (fraccrp) antibodies and assays


antibodies and antigen-binding fragments of antibodies that bind to human fractional c-reactive protein (fraccrp), kits containing these antibodies and antibody fragments, and assays using these antibodies and antibody fragments.. .
University Of Massachusetts
03/12/15
20150071954

Stable peptide mimetics of the hiv-1 gp41 pre-hairpin intermediate


The present invention relates to a gp41 trivalent peptide mimetic having three gp41 n-peptides on a chemical scaffold which conformationally constrains the n-peptides into a trimeric coiled-coil to mimic gp41 presentation. The present invention also relates to n-peptides having the entire hiv gp41 nh2-terminal heptad repeat region and which are capable of forming gp41 peptide mimetics.
03/12/15
20150071945

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
03/12/15
20150071943

Antibody formulation


The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide.. .
Medimmune, Llc
03/12/15
20150071942

Combination therapy of anti-mif antibodies and chemotherapeutics


The present invention pertains to anti-mif antibodies, in particular their use in combination with therapeutics, i.e. Chemotherapeutics, in the treatment of cancer..
Baxter International Inc.
03/12/15
20150071940

Single domain antibodies capable of modulating bace activity


Described are single domain antibodies with a specificity for bace1. More specifically, described are single variable-domain antibodies derived from camelids that bind to bace1 and are capable of inhibiting the activity of bace1.
Katholieke Universiteit Leuven, K.u. Leuven R&d
03/12/15
20150071939

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
03/12/15
20150071937

Internalizing human monoclonal antibodies targeting prostate cancer cells in situ


This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens..
The Regents Of The University Of California
03/12/15
20150071936

Pharmaceutical formulations of tnf-alpha antibodies


The present invention provides certain improved formulations of proteins. Specifically, the present invention provides use of certain excipients that are useful for stabilization of antibody preparations.
Cadila Healthcare Limited
03/12/15
20150071931

Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same


The invention provides lm-1 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. The invention also provides antibodies, functional fragments, modified and variant forms that bind to lm-1 antigen (e.g., nono/nmt55).
Patrys Limited
03/12/15
20150071929

Anti-nkg2a antibodies and uses thereof


Described herein are anti-nkg2a antibodies suitable for human therapy, including humanized versions of murine anti-nkg2a antibody z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (cdrs) sequences and sites for optional amino acid back-substitutions in framework region (fr) and/or cdrs of such antibodies are also described..
Novo Nordisk A/s
03/12/15
20150071927

Anti-her2 and anti-igf-ir bi-specific antibodies and uses thereof


Disclosed are antibodies, or binding fragments thereof, that specifically bind to human her2 and human igf-ir. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules.
The University Of Hong Kong
03/12/15
20150071924

Anti-angiogenesis therapy for the treatment of previously treated breast cancer


This invention concerns in general treatment of diseases and pathological conditions with anti-vegf antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-vegf antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer..
Genentech, Inc.
03/12/15
20150071923

Modified anti-epidermal growth factor receptor antibodies and methods of use thereof


Provided herein are modified anti-egfr antibodies and nucleic acid molecules encoding modified anti-egfr antibodies. Also provided are methods of treatment and uses using modified anti-egfr antibodies..
03/12/15
20150071917

Methods and products for evaluating an immune response to a therapeutic protein


The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of vla4 binding antibody (e.g., natalizumab).
Biogen Idec Ma Inc.
03/12/15
20150071916

Anti-cd28 humanized antibodies


The invention relates to humanized antibodies directed against the human lymphocyte receptor cd28. When used in a monovalent form these antibodies are antagonists, i.e.
Institut National De La Sante Et De La Recherche Medicale (inserm)
03/12/15
20150071915

Monoclonal antibodies against amyloid beta protein and uses thereof


The subject invention relates to monoclonal antibodies (e.g., 8f5 and 8c5) that may be used, for example, in the prevention, treatment and diagnosis of alzheimer's disease or other neurodegenerative disorders.. .
Abbvie Deutschland Gmbh & Co Kg
03/12/15
20150071912

Prophylaxis of colorectal and gastrointestinal cancer


The present disclosure provides methods and compositions useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, having pre-cancerous adenomatous polyps. The present disclosure provides compositions comprising anti-pg antibodies suitable for use in the methods of the disclosure.
Centre National De La Recherche Scientifique (cnrs)
03/12/15
20150071875

Human antibodies that bind human il-12 and methods for producing


Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hil-12) are disclosed. Preferred antibodies have high affinity for hil-12 and neutralize hil-12 activity in vitro and in vivo.
Abbott Gmbh & Co., Kg
03/12/15
20150071854

Human monoclonal antibodies against hendra and nipah viruses


The present invention relates to monoclonal antibodies that bind or neutralize hendra or nipah virus. The invention provides such antibodies, fragments of such antibodies retaining hendra or nipah virus-binding ability, fully human antibodies retaining hendra or nipah virus-binding ability, and pharmaceutical compositions including such antibodies.
The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt
03/12/15
20150071853

Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof


The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal.
Immune Pharmaceuticals Ltd.
03/12/15
20150071852

Foxc1 antibodies and methods of their use


In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human foxc1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer.
John Wayne Cancer Institute


Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         











0.8195

4014

459098 - 0 - 87